IGF-1 LR3
A long-acting insulin-like growth factor analog discussed in physique and performance communities rather than approved peptide medicine.
Also referenced as: Long R3 IGF-1
Also appears in: GH axis
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when IGF-1 LR3 crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Performance. Also surfaces under GH axis for browsing and discovery.
Long R3 IGF-1
No FDA label signal · 0 trials · 17 PubMed results
Current evidence for IGF-1 LR3 is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
IGF-1 LR3 has no clinical trials that name it and 12 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What IGF-1 LR3 is
IGF-1 LR3 is a modified insulin-like growth factor analog designed for a longer activity profile than native IGF-1. It is usually discussed in physique, recovery, and performance circles rather than in standard FDA-approved therapeutic practice.
Why it matters
This profile belongs in the library because “muscle growth peptides” is one of the most searched peptide buckets online, and readers need at least one clearly labeled example of that category.
Regulatory context
IGF-1 LR3 is not an FDA-approved peptide therapy in the way licensed medicines are. It should be read as a research-market/performance-adjacent compound, not as a mainstream medical treatment.
Practical reading note
This is exactly the kind of profile where category clarity matters: muscle-growth demand is high, but evidence quality, legality, and product quality are all much messier than the marketing usually implies.